Hydra Biosciences is a privately held clinical-stage biopharmaceutical company based in Cambridge, Massachusetts that was founded in 2001. The company specializes in developing drugs to treat pain, inflammation, renal disease, anxiety, and pulmonary disease by leveraging its expertise in novel ion channels. Utilizing its proprietary platforms, Hydra Biosciences is able to identify and develop drug candidates that address significant unmet medical needs. The company's latest funding round was a $10.51M Series E investment on 31 March 2015.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series E | $10.51M | - | 31 Mar 2015 | |
| Series D | $22.00M | 7 |
|
16 Jan 2009 |
| Series C | $34.00M | 6 |
|
13 Mar 2008 |
| Series B | $18.87M | 8 |
|
12 Jan 2004 |
| Series A | $9.30M | 5 |
|
26 Jul 2002 |
No recent news or press coverage available for Hydra Biosciences.
We care about your data, and we'd love to use cookies make your experience better.
